Key terms
About GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GKOS news
Mar 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Mar 25
6:00am ET
Glaukos price target raised to $120 from $107 at Citi
Mar 22
7:07am ET
Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)
Feb 28
7:13am ET
Glaukos to Present Periodic Investor Updates Online
Feb 25
11:56pm ET
Glaukos Corporation: Hold Rating with Cautious Optimism Amidst iDose Launch and Reimbursement Uncertainties
Feb 22
8:34am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Moderna (MRNA) and Glaukos (GKOS)
Feb 22
8:03am ET
Piper Sandler Sticks to Its Buy Rating for Glaukos (GKOS)
Feb 22
7:27am ET
Buy Rating for Glaukos: A Comprehensive Analysis of Growth Drivers and Financial Stability
Feb 22
7:17am ET
Glaukos price target raised to $102 from $90 at BTIG
Feb 22
6:49am ET
Glaukos price target raised to $103 from $83 at Wells Fargo
Feb 22
6:29am ET
Glaukos price target raised to $107 from $101 at Citi
Feb 22
5:30am ET
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS) and Glaukos (GKOS)
Feb 21
4:25pm ET
Glaukos affirms FY24 revenue view of $350M-$360M, consensus $356.3M
Feb 21
4:25pm ET
Glaukos reports Q4 EPS (63c), consensus (55c)
Feb 21
4:24pm ET
Glaukos Quarterly Summary: Performance Insights and Disclosures
Feb 16
7:37am ET
Piper Sandler Gives a Buy Rating to Glaukos (GKOS)
Feb 16
5:29am ET
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Glaukos (GKOS)
Jan 30
9:30pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Stryker (SYK), BioMarin Pharmaceutical (BMRN) and Glaukos (GKOS)
Jan 10
5:40am ET
Analysts Are Bullish on These Healthcare Stocks: Icon (ICLR), Glaukos (GKOS)
Jan 09
7:06am ET
Glaukos backs FY24 revenue view $350M-$360M, consensus $352.71M
Jan 09
7:05am ET
Glaukos raises FY23 revenue view to $313M from $307M-$310M, consensus $309.02M
Jan 09
7:03am ET
Glaukos reports preliminary Q4 revenue $81M, consensus $76.66M
Jan 07
5:32am ET
BTIG Remains a Buy on Glaukos (GKOS)
Jan 02
9:18am ET
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
Dec 31
5:10am ET
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
Dec 29
7:59am ET
MIGS LCD withdrawals ‘takes some upside off table’ for Glaukos, says Truist
Dec 27
5:41am ET
Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Gracell Biotechnologies (GRCL) and Glaukos (GKOS)
No recent news articles are available for GKOS
No recent press releases are available for GKOS
GKOS Financials
Key terms
Ad Feedback
GKOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GKOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range